Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TSHA Taysha Gene Therapies

Watchlist
2.080
-0.050-2.35%
Close 10/04 16:00 ET
2.08000.00%
Post Mkt Price 10/04 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.210
Open
2.100
Turnover
177.04K
Low
2.010
Pre Close
2.130
Volume
84.86K
Market Cap
85.47M
P/E(TTM)
Loss
52wk High
19.114
Shares
41.09M
P/E(Static)
Loss
52wk Low
1.680
Float Cap
51.56M
Bid/Ask %
-83.33%
Historical High
33.350
Shs Float
24.79M
Volume Ratio
0.70
Historical Low
1.680
Dividend TTM
--
Div Yield TTM
--
P/B
2.61
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.34%
Amplitude
9.39%
Avg Price
2.086
Lot Size
1
Float Cap
51.56M
Bid/Ask %
-83.33%
Historical High
33.350
Shs Float
24.79M
Volume Ratio
0.70
Historical Low
1.680
Dividend TTM
--
P/B
2.61
Dividend LFY
--
Turnover Ratio
0.34%
Amplitude
9.39%
Avg Price
2.086
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
CEO: Session II, R. A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top